Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: A Cardiac MRI Study



Status:Recruiting
Conditions:HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:40 - 75
Updated:1/16/2019
Start Date:July 31, 2017
End Date:July 2020
Contact:Tomas Neilan, MD
Email:tneilan@mgh.harvard.edu
Phone:617-724-5351

Use our guide to learn which trials are right for you!

In this study, investigators plan to test whether statins can preserve and/or improve
diastolic function among asymptomatic persons with HIV who are on anti-retroviral therapy.
Both myocardial fibrosis and myocardial steatosis are thought to contribute to diastolic
dysfunction and eventually overt heart failure in HIV. HIV-positive participants will undergo
cardiac MRI/MRS imaging studies for the evaluation of myocardial fibrosis and myocardial
steatosis prior to initiation of statin or placebo therapy and then two years after
initiation of statin or placebo therapy. Traditional markers of cardiovascular (CVD) risk,
systemic immune activation/ inflammation, HIV-specific parameters (i.e. CD4 count), and
markers of myocardial stretch/injury will be assessed in relation to cardiac MRI/MRS
outcomes.


Inclusion Criteria:

- New enrollment in the REPRIEVE Trial

Exclusion Criteria:

- clinical diagnosis of HFpEF or HFrEF, by subject report

- standard contraindications to MRI procedure based on MRI Patient Procedure Screening
Form - including history of severe allergy to gadolinium
We found this trial at
4
sites
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Cape Town,
Click here to add this to my saved trials
5323 Harry Hines Blvd
Dallas, Texas 75390
?
mi
from
Dallas, TX
Click here to add this to my saved trials
11301 Wilshire Boulevard
Los Angeles, California 90073
Phone: 310-268-3643
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials